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Background: Urothelial bladder cancer is a highly heterogeneous disease. Cancer cell lines are useful tools for its
study. This is a comprehensive genomic characterization of 40 urothelial bladder carcinoma (UBC) cell lines including
information on origin, mutation status of genes implicated in bladder cancer (FGFR3, PIK3CA, TP53, and RAS), copy
number alterations assessed using high density SNP arrays, uniparental disomy (UPD) events, and gene expression.
Results: Based on gene mutation patterns and genomic changes we identify lines representative of the FGFR3-driven
tumor pathway and of the TP53/RB tumor suppressor-driven pathway. High-density array copy number analysis identified
significant focal gains (1q32, 5p13.1-12, 7q11, and 7q33) and losses (i.e. 6p22.1) in regions altered in tumors but
not previously described as affected in bladder cell lines. We also identify new evidence for frequent regions of
UPD, often coinciding with regions reported to be lost in tumors. Previously undescribed chromosome X losses
found in UBC lines also point to potential tumor suppressor genes. Cell lines representative of the FGFR3-driven
pathway showed a lower number of UPD events.
Conclusions: Overall, there is a predominance of more aggressive tumor subtypes among the cell lines. We
provide a cell line classification that establishes their relatedness to the major molecularly-defined bladder tumor
subtypes. The compiled information should serve as a useful reference to the bladder cancer research community
and should help to select cell lines appropriate for the functional analysis of bladder cancer genes, for example
those being identified through massive parallel sequencing.
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Urothelial bladder cancer (UBC) has a high incidence,
with 133,696 new cases and 51,056 deaths from UBC in
Europe in 2011 [1] and a high prevalence due to the fact
that it is commonly an indolent disease. UBC has a
higher incidence in males than in females (3:1) and it is
the fourth most common cancer in men. Age, smoking,
chlorination byproducts, and occupational exposures are
the major risk factors [2].* Correspondence: preal@cnio.es
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creativecommons.org/publicdomain/zero/1.0/UBC displays a high level of clinical and pathological
heterogeneity. Morphologically, tumors can show papil-
lary vs. solid growth patterns. A clinically relevant issue
is the level of invasion of the bladder wall: tumors are
classified as non-muscle invasive (NMIBC, Ta, carcin-
oma in situ, and T1) or muscle-invasive (MIBC, ≥T2).
The majority of patients (ca. 70%-80%) present with
papillary NMIBC, most of whom have a good prognosis.
Patients with high-grade NMIBC, and those with MIBC,
have an aggressive disease that can lead to patient’s
death, emphasizing the need to better classify these
tumor subgroups.
Approximately 70% of NMIBC harbour activating mu-
tations in FGFR3, the main oncogene involved in UBC
[3-5]. PIK3CA mutations occur in 15% of UBC, often inle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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10% of tumors have mutations in RAS genes, mutually
exclusive with FGFR3 mutations [7]. MIBC tend to have
a low frequency of mutations in FGFR3 (10%) and de-
velop predominantly through the inactivation of the P53
and RB pathways [4,8,9]. Unlike NMIBC, these tumors
are genomically unstable [4,10,11]; several studies have
reported the most commonly gained and lost regions
[11,12]. TERT promoter mutations occur in >70% UBC,
regardless of stage/grade [13].
Tumor cell lines are invaluable research tools. They
are readily amenable to experimental manipulation, pro-
viding opportunities for functional analyses and contrib-
uting to improved knowledge [14]. Cell lines have
proven useful in preclinical pharmacological studies [15]
and will be very important to characterize the function
of new cancer genes identified through massive parallel
sequencing. However, cell lines often fail to faithfully re-
flect the genetic and phenotypic diversity of primary
tumors and do not fully recapitulate their complexity be-
cause the stromal and inflammatory components are not
represented in vitro. In addition, tumor cells may behave
differently in vitro due to the lack of interactions with
non-neoplastic cells. Therefore, a thorough knowledge
of their genotype and phenotype is essential in order to
optimize their use while considering their limitations.
Cell lines from primary UBC are commonly used as
disease models. It is crucial to identify those lines best
suited to answer specific biological questions and to
place the studies in the context of patient’s tumors. The
genetic make-up of UBC cell lines has been analyzed
using array comparative genomic hybridization [16].
High-resolution gene copy number information for 24
UBC lines is published as part of The Cancer Cell Line
Encyclopedia [14] but a detailed comparison of muta-
tions, gene copy number changes, and gene expression
is not available. Importantly, the NCI-60 panel does not
contain any UBC line [15]. Here, we compile high-
resolution genomic information on the largest panel of
UBC lines analyzed so far and provide a comprehensive
overview of their genetic/genomic architecture. In
addition, we use the global transcriptomics data to place
the cell lines in the context of the recently reported mo-
lecular taxonomy of UBC. This will serve as a reference
to the bladder cancer research community and will help
to select the most adequate cells to answer specific bio-
logical questions.
Results
We report here a detailed genomic analysis of a large set
of UBC cell lines in order to improve their use as models
for the study of this tumor type. Web resources used are
listed in Additional file 1: Table S1. Mutations were
assessed for 49 lines, copy number changes were analyzedin 42 lines, and global expression profiles were gathered
for 48 lines. For 40 of them (UBC-40 panel), the complete
set of analyses is provided. A summary of the literature
search, and our own results, is shown in Table 1 and
Additional file 1: Table S2.
The genomic architecture of UBC lines
Information on 902,103 autosomal probes covering
2,787 Mb of the genome was analyzed using the
waviCGH web server. All of these probes were called as
altered (copy number lost or gained) in ≥10 cell lines.
An average of 1349 Mb (510-2111 Mb) were altered
across the panel: 592 Mb were gained (219-1189 Mb)
and 757 Mb were lost (180-1291 Mb). The line showing
the lowest fraction of the (autosomal) genome altered
was MGH-U3 (510 Mb, 18.3% of the covered genome).
639V cells showed the highest fraction of gains/losses:
2111 Mb (75.8%) (Table 1, Figure 1). The remaining
lines showed variable fractions of the genome altered
over a continuum; no discrete categories could be identi-
fied (Figure 1). Losses were more frequent than gains: an
average 28% of covered genome was lost as compared to
21% gained (P = 0.0005). Most cell lines showed loss or
gain of multiple whole chromosomes (Figure 1).
Alterations in oncogenes and tumor suppressors
Table 1 shows the mutational status of UBC-relevant
oncogenes and tumor suppressors. Figure 2A and
Additional file 1: Table S3 summarize these results and
compare mutation prevalence in cell lines and in
primary UBC using information retrieved from the
COSMIC database. FGFR3 mutations were significantly
less frequent in cell lines than in tumors (20% vs. 46%,
P = 1.9x10-4). RT112 and RT4 cells exhibited amplifica-
tion of a 75 and 79 Mb region, respectively, encompass-
ing FGFR3 and part of the neighboring TACC3. FGFR3
mRNA expression was higher in FGFR3-mutant lines
(P = 0.09) (Figure 2C). These two lines, and SW-780,
have recently been shown to harbour activating transloca-
tions involving FGFR3 [17]. PIK3CA mutation frequency
was similar in lines and UBC tissues (24% vs. 19%, P = 0.3).
Five of 45 lines (11%) harbored a mutation in both FGFR3
and PIK3CA, comparable with the frequency in COSMIC
UBC tissues (16%, P = 0.6). Mutations in HRAS (7%), KRAS
(8%), NRAS (5%), and AKT1 (5%) were less frequent
(Table 1, Figure 2A, and Additional file 1: Table S3). UM-
UC-7 demonstrated amplification of a 7.4 Mb region in-
cluding KRAS. There were no amplifications in PIK3CA,
HRAS, or NRAS.
To assess the status of key tumor suppressors (INK4A,
PTEN, and TP53) both mutations and genomic losses
were considered (Table 1 and Figures 2A and B). VM-
CUB-1 was the only line harboring a point mutation in
INK4A; gene losses were present in 63% of cell lines,
Table 1 Genetic characterization and copy number analysis of the major oncogenes and tumor suppressor genes invo ed in UBC cell lines
Name Source Grade Sex FGFR3 PIK3CA HRAS KRAS2 NRAS TERT INK4A CN
status
TP53 (Mutation/CN) Genome instability
group
253J UCC G4 F WT1,4 E545G2,4 WT4 WT1 WT4 WT11 HD 1,4 WT/N3 Intermediate
5637 UCC G2 M WT1,4 WT1,4 WT1,4 WT4 WT1 Mut11 WT1,4 c.839G > C/N1,2,3 Intermediate
575A UCC G3 M WT1,4 WT4 WT WT/LOH1 Intermediate
639V UCC G3 M WT1,4/R248C2 A1066V1,2,4 WT1,4 WT1/G12D2 WT1/H131R2 Mut11 LOH4 c.743G > A/N1,2,3 High
92-1 UCC G3 F WT1,4 WT4 WT4 WT4 WT4 Mut11,12 WT6,4 cd 158, 162, 228, 280 &
294/N6,8
Intermediate
96-1 UCC G2/3 M WT1,4 WT4 WT4 WT4 WT4 Mut11,12 HD6 cd 175/N6,8 Intermediate
97-1 UCC G1/2 M WT1,4 WT4 WT4 WT4 WT4 WT11 HD6 WT/LOH6,8 LOW
97-18 UCC G3 Y WT1,4 WT4 WT4 WT4 WT4 Mut11,12 LOH4 cd 220/LOH8 High
97-24 G3 Y WT1,4 WT4 WT4 WT4 WT4 Mut11,12 WT4 cd 275/N8 High
97-7 UCC G2/3 Y S249C1 WT4 WT4 WT4 WT4 Mut11 WT4 cd 128/N8 High
BC61 UCC G2 Y G372C4,10 WT4 WT4 WT4 WT4 WT4 WT/N Low
HT1197 UCC G4 M S249C1,4 E545K1,4 WT1,4 WT1 WT1/Q61R4 Mut11,12 WT1 WT1/c.1094A- > G3
HT1376 UCC G3 F WT1,4 WT1,4 WT1,4 WT1 WT1 Mut11 WT1,4 c.749C > T/LOH1,2,3 Low
HU456 G1 M WT4 G12S4 WT4 WT12 HD4 WT/N7 Intermediate




JON UCC WT1/S249C1 WT4 WT4 WT4 WT4 Mut11/WT12 Mut4
KK47 G1 M WT4 WT4 WT4 WT12 WT4 N High
LGWO1 G600 WT1,4 WT4 WT4 G12C4 WT4 WT12 HD4 LOH Low
MGH-U3 UCC G1 M Y375C4/Y373C1 WT4 WT4 WT4 WT4 Mut11,12 HD4 WT/N4 Low
MGH-U4 focal severe
urothelial atypia
G1 M WT1,4 H1047R4 Mut12 HD4 WT/N4 Low
PSI UCC G3 M WT4 WT4 WT4 Mut12 WT7
RT112 UCC G2 F WT1,2,4/Amp4/FGFR3-TACC3
fusion 13
WT1,4 WT1,4 WT1 WT1 Mut11,12 HD1,4 c.743G > A&c.548C- >
G/LOH1,2,3
Low
RT4 UCC G1 M WT1,4/Amp4/FGFR3-TACC3
fusion 13
WT1 WT WT1 WT1 Mut11,12 HD1,4 WT/LOH1,3 Low
SCaBER SCC M WT1,2,4 WT WT4 WT4 WT1 Mut11,12 LOH4 c.329G > T/LOH2,3 Intermediate
SW-1710 UCC F WT1,2,4 WT1,4 WT1,4 WT1 WT Mut11,12 HD1 c.817C > T/LOH1,2,3 High
SW-800 UCC M WT1,4 WT4 WT4 WT4 WT4 Mut12 HD4 WT/N4 Low












Table 1 Genetic characterization and copy number analysis of the major oncogenes and tumor suppressor genes involved in UBC cell lines (Continued)
SW-780 UCC G1 F WT1,2/S773F2/FGFR3-BAIAP2L1
fusion 13
WT1, WT1 WT1 WT1 Mut12 HD4 WT/N1 Low
T24 EC G3 F WT1,4 WT1,4 G12V1,4 WT1 WT1 Mut11,12 WT1/LOH4 c.378C > G/N1,3 Low
TCCSUP UCC G4 F WT1,4 E545K1 WT1,4 WT1 WT1 Mut11,12 WT1 c.1045G > T/LOH1,3 Intermediate
UM-UC-1 UCC-LN G2 M WT1 WT4 WT4 WT4 WT4 HD4 c.454C- > T/LOH2,3,5 Intermediate
UMUC- 2 UCC CIS M WT1 Mut12 WT5
UM-UC-3 UCC M WT1,4 WT1,4 WT1,4 G12C1,2,4 WT1 Mut11 HD1/WT4 c.338 T > G/N1,3,5,9 High
UM-UC-4 UCC-LC F WT4 WT4 WT4 LOH High
UM-UC-5 F WT4 E545K4 WT4 WT4 WT4 Mut12 HD4 LOH Intermediate
UM-UC-6 UCC M WT1/R248C4 E545K4 WT4 HD4 WT/LOH1,5,9 Low
UM-UC-7 M WT4 WT4 WT4 Mut12 WT4 LOH Intermediate
UM-UC-9 UCC WT4 WT4 WT4 Mut12 LOH4 Mut/LOH5,9 Intermediate
UM-UC-10 UCC WT4 WT4 WT4 WT4 WT4 Mut12 Mut5
UM-UC-11 UCC WT4 WT4 WT4 WT4 WT4 Mut12 HD4 WT/N5 High
UM-UC-12 UCC Y WT4 WT4 WT4 WT4 WT4 WT4 N High
UM-UC-13 UCC-LN Y WT4 WT4 WT4 WT4 WT4 Mut12 LOH4 Mut/N5 High
UM-UC-14 UCC Y S249C1 WT4 Mut11,12 HD4 Mut/LOH5,9 Low
UM-UC-15 UCC Y375C4 E545K4 WT4 WT4 WT4 Mut12
UM-UC-17 S249C4 WT4 HD4 LOH Intermediate
UM-UC-18 WT4 WT4 Q61K4 WT4 WT4 Mut12 WT4 N High
VM-CUB-1 EC G2 M WT1 WT1/E542K +
E674Q2
WT1 WT1 WT1 Mut11,12 c.322G >
C1/LOH4
c.524G > A&c.378C- >
G/LOH1,23
High
VM-CUB-2 EC M WT1,4 WT4 WT4 WT4 WT4 Mut11 HD1,4 c.473G- > T&c.488A- >
G/LOH3
High
VM-CUB-3 EC G3 M WT1,4 E545K4 WT4 WT4 WT4 Mut11 HD4 c.833C- > T/N3 Low
All TERT mutations were -124 bp(G > A) except the line marked as #-57 bp(T > G).
Amp, amplification; WT, wild type; Mut, mutant; LOH, loss of heterozygosity; HD, homozygous deletion; N, copy number neutral; Y, Y chromosome detected.
1COSMIC database; 2CCLE database; 3IARC database1, COSMIC database; 2, CCLE database; 3, IARC database; 4our data; 5Specific TP53 mutation is not specified. [35]; 6TP53 mutation determined by expression analysis












Figure 1 Genomic alterations in cell lines included in the UBC-40 panel. (A) Fraction of the genome altered (gains and losses). (B) Whole
chromosome and whole chromosome arm alterations in the cell lines. (C) Fraction of the genome affected by UPDs.
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homozygous deletions (HD) (n = 20). INK4A mRNA ex-
pression was significantly lower in lines with LOH
(defined as gene copy number loss) or HD than in wild
type lines (Figure 2D). As of PTEN, 23% and 19% of the
lines harboured mutations or LOH. J82 and UM-UC-3
had a PTEN mutation and a partial HD. 639V, T24, and
UM-UC-9 harboured a missense mutation and retained
a wild type allele whereas 5637, RT4, and SW-780 were
wild type and showed LOH. Cell lines with LOH or mu-
tant PTEN had a significantly lower expression of PTEN
mRNA than wild type lines (Figure 2E). PTEN mutations
were also significantly more frequent in cell lines than in
tumor tissues (23% vs. 4%, P = 1.04x10-4). Regarding
TP53, mutations were significantly more frequent in cell
lines than in tumors (66% vs. 31%, P = 2.7x10-6). LOH
was found in 47% of the lines.
Figure 2B compares the frequency of tumor suppres-
sor gene losses in cell lines and tissues analyzed using
the same assay platform (n = 49), categorized as non-
aggressive vs. aggressive. Gene loss in cell lines and ag-
gressive tumors was comparable (P = 0.64). However,
non-aggressive tumors showed a lower frequency ofalterations as compared to cell lines (P = 0.02). The fre-
quency of INK4A and PTEN loss was similar in cell lines
and tumors (P = 0.3) but the frequency of TP53 LOH
was higher in cell lines (47% vs. 28%, P = 0.06).
Original tumor grade, oncogene/tumor suppressor status,
and genomic instability
The grade of the original tumor from which 27 lines
were isolated was available (Additional file 1: Table S2).
Genomic instability, assessed as the size of the genome
with copy number alterations, was compared in samples
harbouring - or not - mutations in UBC oncogenes and
tumor suppressor genes.
In agreement with the genomic analyses of tumors,
FGFR3 mutant lines showed lower genomic instability
(genome altered: 1024 ± 461 Mb vs. 1402 ± 349 M, P = 0.06,
Wilcoxon). By contrast, TP53 mutant lines showed higher
genomic instability (genome altered: 1381 ± 366 Mb vs.
1023 ± 433 Mb, P = 0.04) (Additional file 2: Figure S1 and
Additional file 1: Table S4). Cell lines isolated from
low-grade tumors (G1/G2) tended to be more stable
than those isolated from high-grade tumors (G3/G4)
(Additional file 2: Figure S1). Similar tendencies were
AC D E
B
Figure 2 Alterations in the most relevant oncogenes and tumor suppressors involved in UBC. (A) Comparison of mutation frequency in UBC
lines and tumors. (B) Frequency of LOH or homozygous deletion of tumor supressor genes in UBC lines and tumors. (C) Association between
FGFR3 mutation status and mRNA expression. (D) Association between INK4A copy status and mRNA expression. (E) Association between PTEN
copy status and mRNA expression. HD = Homozygous deletion, LOH = Loss of heterozygosity, WT =Wild type.*P < 0.05 **P < 0.01.
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instability (total size of the genome altered, fraction of
probes altered, or number of altered segments identified;
see methods section). FGFR3 mutant lines tended to fall
within the genomically stable group whereas TP53 mutant
and high-grade lines tended to fall within the genomically
unstable-high group (Additional file 1: Table S5).
Copy number changes involving whole chromosomes/
whole chromosome arms
Because distinct mechanisms lead to alterations in whole
chromosomes or chromosome arms and to interstitialTable 2 Frequency of whole chromosome or chromosome arm
Chromosome 1 2 3 4 5 6 7 8 9
Losses Whole chromosome 5 9 2 34 2 2 0 0 7
p-arm 9 5 25 9 2 5 5 52 2
q-arm 2 18 0 11 9 5 0 0 5
Gains Whole chromosome 0 0 0 0 11 2 23 2 7
p-arm 2 9 0 2 45 9 18 0 1
q-arm 18 2 34 0 2 9 7 39 1changes, these were assessed separately. Most cell lines
showed losses and gains of multiple whole chromosomes/
whole chromosome arms (Figure 1, Table 2, and Additional
file 1: Table S6). Chromosomes most frequently gained
were chr.20 (41%), chr.7 (23%), chr.21 (20%), and chr.5
(11%). The chromosome arms most frequently gained in-
cluded 5p (45%), 8q (39%), 3q (34%), 7p (18%), 9q (18%), 1q
(18%), 20q (16%), 20p (14%), and 9p (11%). Chromosomes
most frequently lost were chr.4 (34%), chr.1 (27%), chr.21
(25%), chr.15 (20%), chr.22 (20%), chr.13 (16%), and chr.16
(16%). The most common arm losses included 8p (52%),
18q (25%), 3p (25%), 9p (23%), 17p (20%), and 2q (18%).alterations in UBC lines (n = 42)
10 11 12 13 14 15 16 17 18 19 20 21 22
11 0 7 16 7 20 16 2 27 9 2 25 20
3 9 14 5 7 0 2 2 20 5 7 2 0 0
9 0 2 2 0 2 0 0 25 7 0 0 0
0 0 2 7 7 2 0 7 0 2 41 20 7
1 7 7 9 0 0 0 0 5 5 2 14 2 0
8 2 7 5 7 2 0 7 5 0 5 16 0 0
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Figure 3 shows copy number calls of individual probes
for each line; Table 3 shows statistically significant
minimal common regions (MCRs) identified using
waviCGH, a permutation-based method [18]. Altogether,
21 statistically significant (FDR <0.05) MCRs were
identified (11 gained and 10 lost), ranging from 1.6 kb-
156 Mb in size (gains: 211 Kb-56 Mb; losses: 1.6 Kb-
156 Mb). Six MCRs almost entirely covering chromosome
4 were identified; some MCRs overlapped with whole
chromosome or chromosome arm changes, such as gains
in 1q, 3q, 5p, 7, and 21 and losses in 3p, 4, and 15. Other
MCRs included gains at 11p15 and losses at 6p22.1-6p22.2,
10q23.33, and 13q33.3 (Tables 2 and 3, Figure 3, and
Additional file 1: Table S6). All recurrent focal losses
were hemizygous.
Eight regions were amplified in ≥3 cell lines (81 Kb-
73 Mb) (Additional file 2: Figure S2 and Table 4), mostly
in chromosomes or chromosome arms lacking high
frequency alterations. Six of them have previously been
described as gained/amplified in UBC tissues but not inFigure 3 Genome wide copy number calls across the genome in UBC linecell lines; another region at 12p11.22-12q13.13 is novel
to both tumors and cell lines.
X chromosome analysis
Data regarding the X chromosome could be evaluated in
37 lines (9 female and 28 male). Large structural alter-
ations were rare: 6 lines showed complete loss of Xp
whereas 3 lines showed almost complete gain of Xq. No
significant MCRs were identified although peak gains
were seen at Xp22.2, Xp11.4, Xp11.23, Xq11.2, Xq12,
and Xq25 and peak losses at Xq21.31 and Xp21.3-21.1
(Additional file 2: Figure S3).
Uniparental disomies (UPD)
Autosomes were analyzed for the presence of UPD
(Figure 4 and Additional file 1: Table S7), defined as
copy number neutral or amplified regions showing
LOH. Examples of different categories of UPD events
are shown in Additional file 2: Figure S4A-F. Overall,
195 UPD events were identified in 40 lines: UPDs
were absent from BC61, RT4, and MGH-U3. Interestingly,s. Gender and oncogene/tumor suppressor status are also annotated.
Table 3 Focal gene copy number alterations and minimal common regions (MCR) identified using waviCGH in UBC lines
Variation
type






CytoBand (Probe boundaries) Number of
genes
Previously described
GAIN 1 15995 4751 0.05 35 1q25.3-1q31.3 (rs502870- rs590258) 164 Tumors: 1q gain, 1q24.2
and 1q23 amplification
SETDB1 (1q21)
1 1517 695 0.05 38 1q32.2 (rs1126573- rs2494606) 0 Novel
3 4084 1623 0.02 35 3q21.3-3q22.1 (rs34267791-rs6439205) 110 3q21.3 tumors
5 49651 16712 0.05 35 5p13.1-5p12 (rs28538767- rs36047540) 609 Novel
7 55653 22123 0.01 42 7p15.2-7p11.2 (rs4096522- rs10280445) 848 7p11.2 amplification high
grade tumors
7 840 347 0.05 38 7q11.23 (rs11544049- rs2074666) 22 Novel




7 211 96 0.05 38 7q33 (rs10260266- rs3807337) 5 Novel
11 3044 1510 0.05 35 11p15.5-11p15.4 (rs4029252- rs7103275) 152 Tumors: 11p loss
LOSS 3 22040 8521 0.04 46 3p21.1-3p14.2 (rs4927997- rs13075591) 240 Tumors/cell lines
4 310 78 0.01 44 4p16.3 (rs10446889- rs13137548) 15 Tumors/cell lines
4 665 272 0.05 40 4p16.3-4p15.1 (rs1728273- rs11930062) 379 Tumors/cell lines
4 4561 2058
4 22491 7467
4 1839 399 0.05 40 4p13-4q35 (rs7665332- rs13124496) 2003 Tumors/cell lines
4 155726 47697 0.01 44
6 4227 3338 0.01 42 6p22.1 (rs498548- rs9468692) 267 MHC region
10 640 424 0.03 40 10q23.33 (rs17110194- rs11188277) 17 Tumors/cell lines
13 1.60 5 0.03 38 13q33.3 (rs3093749- rs1805385) 1 Tumors/cell lines
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the genome altered (Figure 1). All autosomes dis-
played ≥1 UPD event in ≥2 lines. The median number
of UPD events per line was 4; cell line 97-24 showed
22 UPD events. Focal UPDs were the most common
event (n = 91), ranging in size from 2-129 Mb. There
were 51 UPDs involving whole chromosomes and 39
UPDs of a whole chromosome arm. UPDs involvingTable 4 Regions of genomic amplification in UBC lines*
Chr Length (KB) Number of probes Frequency (% Cell Lines)
1 81 42 7-11
3 73857 848 7
6 3837 1516 7-14
11 20016 1462 7-18
11 29380 1165 7-11
12 21857 87 7-9
14 3856 1157 7
17 55108 1298 16-18
*Statistically significant MCR.whole chromosomes were most common in chr. 9, 17,
and 22.
Many UPD events occurred in regions that are lost in
other lines, supporting the occurrence of tumor suppres-
sors therein. For example, region 3p21.1-3p14.2, lost in
46% of lines, coincides with a recurrent UPD. In addition,
4 lines show UPD of chr.3 (639V, 253J, and UM-UC-13)
or 3p arm (96-1). The number of UPD and their totalCytoband Number of genes Previously described
1p36.22 6 Tumors: gain
3p25.2-3p12.1 1052 Cell lines: 3p loss
6p22.3 42 Tumors E2F3
11p11.12-11q13.4 782 Tumors: 11p loss
11q22.1-11q24.2 616 Tumors: 11q loss
12p11.22-12q13.13 452 Novel
14q21.2 26 Tumors: 14q loss
17p11.2-17q25.1 1448 Tumors: 17p loss
Figure 4 Genome wide assessment of regions showing UPD identified in UBC lines.
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copy number alterations (p = 0.08 and p = 0.09) (Additional
file 2: Figure S5). FGFR3 mutant cell lines had significantly
fewer UPD events and overall size of the genome affected
by UPD than wild type lines, supporting that UPD associ-
ates with aggressiveness (Additional file 2: Figure S6).
Gene-level analysis of copy number alterations
Gene copy number data was newly generated from 19
low-risk and 30 high-risk primary UBC. Some gains
(5p, 8q, 17q, and whole chr.20) and losses (5q, 8p, 17p)
occurred with similar frequency in lines and tumors
(Figures 1B, and 5, Table 2, and Additional file 1: Table S6).
Tumors typically showed whole chr.9 loss, likely tar-
geting multiple tumor suppressors (i.e. INK4A, PTCH1,
and TSC1) whereas the cell lines had a high frequency
of both gains and losses of chromosome 9, often in
association with UPD affecting either the wholechromosome or its q-arm (Figure 4). Partial chr. 9 UPDs
were found in several cell lines although there was no
overlap among the regions affected. Chr.19 and chr.22
were more frequently lost in lines whereas they were
more often gained in tumors (Figure 5).
Comparison of gene copy number alterations
and expression
The complete expression dataset is provided in Additional
file 1: Table S8. The 8 regions amplified in ≥3 cell lines
(Additional file 1: Table S9) include 825 protein-coding
genes with microarray expression information; 396 of them
had a higher average expression in lines with gains/amplifi-
cations vs. those without them. This difference was statisti-
cally significant for 51 genes (Additional file 1: Table S9).
Among them are CDKAL1 (CDK5 regulatory subunit asso-
ciated protein like 1, 6p22.3; 4-fold differential expression,
p < 0.05), ASRGL1 (11q13.4), ATP2B4 (1p12), ITGA3,
Figure 5 Genome wide copy number calls in primary bladder tumors (n = 49) with T and G annotation.
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difference between amplified and non-amplified tumors of
1.5-1.9 (p < 0.05).
Gene expression information for 334 genes in the 10
lost regions was available; 225 had a lower average ex-
pression in cell lines with loss vs. those without loss. Of
them, 28 showed statistically significant differential ex-
pression, including ANXA10 (4q32.3; 4.8-fold), ARAP2
(4p14; 2-fold), CDS1 (4q21.23; 2.2-fold), and PTPRG
(3p14.2; 1.6-fold) (Additional file 1: Table S9).
Genomic analyses of new genes involved in UBC
identified through exome sequencing
We analyzed copy number, UPD status, and expression
of new driver UBC genes (Additional file 1: Tables S10
and S11) identified through exome sequencing [19-24].
Several of them are in genomic regions with either
whole chromosome/chromosome arm gain/loss. LOH,
and gains were more common than UPD (average 10 vs.4 events per gene). PDZD2 and CSMD3 were often
gained (41%, 64% and 52% respectively) whereas ANK2,
FAT4 and MLL were often lost (55%, 55% and 50% re-
spectively); MLL is on chromosome 11 - which is not
frequently altered in UBC - and is significantly under-
expressed in cell lines with LOH (Additional file 1:
Table S11). TSC1 showed both gains (52%) and UPD
(29%); a similar pattern was observed for other tumor sup-
pressor genes. TP53 and EP300 were affected by both
LOH and UPD.
UBC cell lines represent molecularly defined bladder
cancer subtypes
We applied the UBC molecular classifier based on gene
expression defined by Sjodahl et al [12] to identify lines
most representative of the taxonomical groups proposed.
Figure 6A shows that cell lines could be adscribed to
the “Urobasal A”, “Urobasal B”, and “SCC-like” classi-
fiers (Additional file 1: Table S12). The “Genomically
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the lines. Rebouissou et al. have recently reported on a
40-gene basal-like signature [25]. We have applied their
40-gene classifier to the cell line dataset and identify 4
major groups: lines with a predominant enrichment in
the “Basal-like” signature; lines with a predominant en-
richment in the “Non basal-like” signature; lines with en-
richment of both signatures; and lines in which none of
the signatures is enriched (Figure 6B and Additional file 1:
Table S13). In agreement with the gene mutation/copy
number change data indicating that cell lines are biased to-
wards a more aggressive type, the “Non Basal/Luminal”
phenotype is less represented among the available estab-
lished cell lines.
Discussion
This is the most comprehensive analysis of the genomic
landscape of UBC lines reported to date, including mu-
tation, copy number, and expression data for a panel of
UBC lines. As we have complete copy number and geneA
Figure 6 Clustering of UBC lines according to the expression of gene sign
displaying expression patterns of the “Urobasal A”, “Urobasal B”, and “SCC-l
defined. (B) Cell lines displaying expression signatures of “Basal-like” or “Non Bexpression data for 40 of them, we have named this
dataset UBC-40.
We provide detailed information on the source of the
cell lines used in order to avoid “mistaken identity”.
When surveying the literature, there are conflicting re-
ports regarding the mutation status of some of the genes
studied possibly due to cell contamination or mislabel-
ing; similar problems have been reported with lines from
the NCI-60 panel [26]. For example, MGH-U1/EJ and
some subcultures of J82 are derived from T24 [27] and
KU7 was cross-contaminated with HeLa [28]. Cell lines
extensively cultured in different laboratories may have
evolved independently and ultimately acquired muta-
tions or genomic changes absent from the original line
[29]. Nevertheless, fundamental features of these cell
lines show stability and have allowed their extensive use
as models of UBC in a wide variety of studies; this is the
case of FGFR3-dependent RT112 cells [30]. The cluster-
ing shown in Figure 6 allows to propose, using two inde-
pendent classifiers, prototype cell lines of papillary/B
atures used to molecularly classify primary tumors. (A) Cell lines
ike” by Sjodahl et al [12]. The “Genomically Unstable” category is poorly
asal-like” tumors according to the classification of Rebouissou et al. [24].
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Basal-like tumors (well represented by several cell lines).
Interestingly, a few cell lines display enrichment in both
Basal and Non-Basal gene signatures (i.e. RT112 and
MGH-U3, both of which are known to be FGFR3-
driven). This information will be useful for selecting the
best models to address specific functional studies.
Most of the lines analyzed here were generated many
years ago, have been extensively passaged, and do
not have matched normal tissue - or lymphoblastoid B
cells - from the same patient available. Therefore, it is
not possible to define the somatic variants they carry,
this being the reason why we have not conducted exome
sequencing. Consequently, and because the lines avail-
able only represent incompletely the spectrum of UBC
as it relates to low-grade tumors, renewed efforts should
be placed in the establishment of new cell lines and
xenografts to facilitate preclinical studies. Improved
sample processing, matrigel embedding, and orthotopic
implantation, as well as more reliable systems for
primary culture and passage [31,32], should contribute
to improve efficiency. Furthermore, efforts should be
made to biobank non-neoplastic material from the same
patients.
The summary data reported here provides an overview
and the detailed datasets should serve as a resource to
the research community in order to identify which -
among these lines - serve best as disease models for spe-
cific tumor subtypes. The recent discovery of new driver
genes involved in UBC through massive parallel sequen-
cing [19-24] and the information provided here should
be useful to select lines appropriate for their functional
analysis and for preclinical studies.
Conclusions
- TP53-mutant lines show high genomic instability
whereas FGFR3- or PIK3CA-mutant lines are more gen-
omically stable.
- We have identified for the first time UPD events in
UBC lines, pointing to new regions containing putative
tumor suppressors.
- We provide novel information on chr. X losses,
where new important tumor suppressor genes have been
identified (i.e. KDM6A and STAG2).
- We identify novel regions deserving research as they
are frequently altered in UCB lines as well as in primary
tumors.
- Some cell lines are more representative of the
FGFR3-driven tumor pathway (RT112, MGH-U3, 97-7,
BC61, RT4, SW-780, and UM-UC-6) whereas others are
more representative of the tumor suppressor-driven
pathways (5637, 92-1, 96-1, 97-18, 97-24, HT1376, SW-
1710, UM-UC-1, UM-UC-13, and VM-CUB-2). We
propose that - as has already been done, in part - thesecells be used as models of non-aggressive and aggressive
UBC, respectively.
- The UBC lines available cover a wide range of tumor
genotypes and phenotypes. While they do not fully rep-
resent the spectrum of tumors found in patients and are
enriched towards a more aggressive genetic architecture,
the main genetic pathways involved in UBC are repre-
sented in this panel.
- Future efforts should be placed to establish new
UBC lines, mainly focusing on less aggressive tumors, as
well as collections of patient-derived xenografts.
Methods
Literature and web-based search
A literature search was performed to retrieve informa-
tion regarding sex, histology, and stage/grade of the ori-
ginal tumor from which the cell line was established, as
well as the original reference. The mutational status of
the main genes involved in UBC (TERT, FGFR3,
PIK3CA, KRAS, HRAS, NRAS, p16/INK4A, PTEN, and
TP53) was analyzed and complemented/supported
through data obtained from COSMIC, CCLE, and IARC
public databases [14,33,34]. Information on mutations in
FGFR3, PIK3CA, KRAS, HRAS, NRAS, PTEN, and TP53
in primary UBC tumors with either “papillary” or
“carcinoma” histology was retrieved from the COSMIC
database. All web resources used in the analysis are
listed in Additional file 1: Table S1.
UBC cell lines
JON, MGH-U4, RT4, SCaBER, SW-800, SW-850, SW-
1710, T24, VM-CUB-2, 253J, 639V, 5637, and 575A
were purchased from the American Type Culture
Collection (Rockville, MD, US); J82, MGH-U3, and
RT112 cells were kindly provided by F. Radvanyi
(Institut Curie, Paris, France); UM-UC-1, UM-UC-3,
UM-UC-4, UM-UC-5, UM-UC-6, UM-UC-7, UM-
UC-9, UM-UC-10, UM-UC-11, UM-UC-12, UM-UC-13,
UM-UC-14, UM-UC-15, UM-UC-17, and UM-UC-18
were provided by H. B. Grossman (MD Anderson Cancer
Center, Houston, TX, US) [35]; HT1197, HT1376, HU456,
KK47, PSI, SW-780, UM-UC-2, and VM-CUB-1 were pro-
vided by D. Theodorescu (University of Colorado, Aurora,
CO); 92-1, 96-1, 97-1, 97-7, 97-18, and 97-24 were gener-
ated by C. Reznikoff [36] and provided by M. Knowles
(University of Leeds, Leeds, UK); TCCSUP was provided
by M. Sánchez-Carbayo (CNIO, Madrid, Spain); BC61 was
provided by W. Schulz [37]; and LGWO1 G600 was pro-
vided by J. Reeder (U. Rochester, NY). Only Mycoplasma-
free cultures were used.
DNA and RNA isolation from cell lines and tumors
Cells were cultured in RPMI supplemented with 10-20%
FBS and were harvested at 70-90% confluence. DNA
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UM-UC-2, and VM-CUB-1 was isolated in the labora-
tory of D. Theodorescu; the remaining cell lines were
cultured at CNIO. DNA was isolated using the DNAeasy
blood and tissue kit (Qiagen) according to manufac-
turer’s instructions.
Tumor samples (n = 49) came from UBC cases di-
agnosed with UBC recruited to the Spanish Bladder
Cancer/EPICURO study. Informed consent was ob-
tained from study participants in accordance with the
Institutional Review Board of the Ethics Committees
of participating hospitals that approved the study
(IRB Hospital del Mar, ref. 2008/3296/1). The T/G
distribution was as follows: Ta (n = 26), T1 (n = 8), T2
(n = 5), T3 (n = 6), and T4 (n = 4); cases were grouped in
two categories, non-aggressive (TaG1 and TaG2) (n = 19)
and aggressive (TaG3 and T1-T4) (n = 30). Only samples
containing >60% tumor cells were used. DNA was isolated
using the Puregene kit A (Qiagen) according to the manu-
facturer’s instructions.
Mutational analyses
FGFR3, PIK3CA, HRAS, KRAS, and NRAS hotspot
mutational analysis was performed using ABI PRISM®
SNaPshot® (ABI) as previously described [38].
Analysis of gene copy number alterations using the
Illumina 1 M Duo array
DNA (1.5 μg) was quantified using picogreen and used
for array hybridization. The Illumina 1 M Duo array in-
cludes 902,103 autosomal probes and 39,779 probes
from sex chromosomes. A total of 43 different cell lines
were hybridized to the arrays (GSE64572) Genotypes
and R values were extracted using the beadstudio soft-
ware (version 3.1.3.0) and R values were normalized
using the method described by Pounds and co-workers
[39]. Log R ratios were calculated using as reference the
average R value from 200 blood leukocyte samples from
control subjects included in the EPICURO study [40]
with the R program version 2.8 [41]. Copy number calls
were obtained using the waviCGH software [18]; seg-
mentation and calling were performed using DNAcopy
[42] and the probability-based method (CGHcall) [43],
respectively. Gene copy number changes were called as
follows: -1 = loss (hemi or homozygous), 0 = copy num-
ber neutral, +1 = gain and +2 = amplification (defined
as ≥5 copies). Minimal common regions (MCRs) were
identified using the permutations method in waviCGH
which computes a P‐value based on a permutation test
assuming that the alterations found are randomly located
in the genome. Consecutive probes with P‐values <0.05
were joined in a common region. Focal copy number alter-
ations are those not involving whole chromosomes or
whole chromosome arms.Gene copy number reproducibility analysis
The experimental reproducibility of the gene copy num-
ber analysis was assessed using data from DNA isolated
in 2 different laboratories (n = 3) or DNA isolated from
different cultures in the same laboratory (n = 5). The ab-
solute call concordance rate was between 79.3 and
96.7%. “Gain/loss” type discordances were very uncom-
mon (0.015-0.03%); most discordances were “gain/no-
change” (1.4-7.5%) or “loss/no-change” (1.9-15.8%). The
replicate with the highest signal to noise ratio was con-
sidered the most accurate and selected for subsequent
analysis. A summary of the call concordance rate in rep-
licates is provided in Additional file 1: Table S14.
Copy number analysis of FGFR3, PIK3CA, KRAS, HRAS,
NRAS, INK4A, PTEN, and TP53
Gene amplification was determined from the copy call
results from CGHcall. LOH and HD were determined by
combining copy call, B allele frequency (BAF), and geno-
typing data. Probes with homozygous calls and BAF of
either 0 or 1 and a decline in the logR ratio of were clas-
sified as LOH and non-called (NC) probes with an ab-
normal BAF and a decline in LogR ratio were classified
as HD. The number of probes representing each gene
was: FGFR3 (n = 22), PIK3CA (n = 42), KRAS (n = 22),
HRAS (n = 2), NRAS (n = 6), INK4A (n = 17), PTEN
(n = 49), and TP53 (n = 22).
Copy number analysis of genes in X chromosome
The gender of the patient from whom the cell lines were
derived was not always available. The presence of a Y
chromosome was considered as a reliable indication that it
was of male origin. This, combined with the data from the
literature, was used to select cell lines for which we could
perform X chromosome gene copy number analysis. The
LogR ratio was calculated with the average R value normal-
ized to a pool of control male or female blood leukocytes
from the EPICURO Study. For probes representing the X
chromosome (38,016 probes), or those corresponding to
sequences present on both the X and Y chromosomes (395
probes), copy number calls were obtained using the
waviCGH software as described for autosomes.
Assessment of genomic instability
Genomic instability was assessed as the fraction of the
genome altered (either lost or gained), calculated from
call data generated by CGHcall using autosome probes
and measured in 3 different ways:
(1) total size of the genome (covered by the Illumina
array) altered. The size in base pairs (bp) of the segmented
regions altered (lost or gained) was calculated from the start
and end position of the segments; (2) fraction of probes
altered - proportion of probes showing loss, gain, and amp-
lification; (3) number of altered segments identified - the
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was determined from the waviCGH segmented call data.
Cell lines were classified in 3 categories according to
fraction of the genome altered (upper, middle, and lower
tertile) calculated by the 3 different methods; low/
medium/high genomic instability groups were thus iden-
tified. We compared the relationship between muta-
tional status in FGFR3, PIK3CA, KRAS, HRAS, NRAS,
p16/INK4A, PTEN, and TP53 and the original tumor
grade with the fraction of the genome altered, calculated
by these approaches. The chi-square test was used to as-
sess the difference between the frequency of mutant vs.
wild type genotypes and low vs. high grade cell lines in
each of the genome instability groups. The Wilcoxon
test was used to assess the difference in the mean of the
genome instability variable between mutant/wild type
and low/high grade cell lines.
Uniparental disomy (UPD) detection
Log R ratios from hybridization data were analyzed
using the zoo package of the R statistical program in
order to identify UPDs [40]. Chromosomal regions with
LOH, as determined from the BAF, and an average LogR
ratio value around 0 indicate a probable segmental UPD.
UPD events were classified into 6 different categories:
(1) involving the whole chromosome, (2) involving a
whole chromosome arm, (3) focal UPD, (4) focal UPD
and segmental duplication, (5) UPD and segmental amp-
lification, and (6) UPD involving almost the entire
chromosome with a combined focal deletion.
RNA expression analyses
We have used previously reported data corresponding to
28 cell lines (GEO: GSE5845) [25] and have generated
expression data for 20 additional cell lines (GSE64279).
RNA was isolated with Trizol in both experimental
batches. For the new cell lines, RNA (500 ng) was ampli-
fied, labeled, and used for array hybridization. The
Affymetrix U133A array was used in all experiments.
Raw expression data from all experiments were nor-
malized using the R library Frozen Robust Multiarray
Analysis (fRMA) method [44]. We applied this method
as described by the authors for multiple arrays. We read
the raw data (CEL files) and used the Random effect
model for preprocessing. This model allows us combin-
ing data from different batches using the same micro-
array platform for analysis. Further, to obtain a matrix of
gene-level expression values we used the exprs function
with parameters by default.
Comparison of gene copy number and expression data
Gene lists were generated for regions identified as sig-
nificant MCRs in copy number lost, gained or amplified
regions. To determine the relationship between genecopy number alteration and expression, correlation ana-
lysis was performed for amplified genes by comparing
copy number amplified/gained cases vs. copy number
neutral/lost cases. For copy number lost genes, a com-
parison of copy number lost vs. no copy number loss
was performed; the difference in expression between the
2 groups was assessed using the Wilcoxon test. The chi-
square test was used to compare the distribution of mu-
tation frequencies in cell lines and tumors.Gene copy number, UPD analysis, and comparison with
expression data of 44 new genes implicated in UBC
Copy number status and UPD of 44 genes recently
shown to be involved in UBC were assessed [20,21,23,24].
To determine the relationship between gene copy number
alteration and expression, correlation analysis was per-
formed for gained genes by comparing copy number
amplified/gained cases vs. copy number neutral/lost cases.
For copy number lost genes, a comparison of copy num-
ber lost vs. no copy number loss was performed; the differ-
ence in expression between the groups was assessed using
the Wilcoxon test.Molecular classification of cell lines according to
expression signatures of primary tumors
A molecular classifier consisting of 1038 genes [12]
was used for hierarchical clustering; M. Lauss kindly
provided the gene expression values for each signa-
ture (Additional file 3) and the classification method
(Additional file 4). We processed the data to obtain
one expression value for each gene present in the
Affymetrix U133A array, as different probes for same gene
are present in the platform. For this purpose we used the
CollapseDataset tool available in the GenePattern webser-
ver with collapse mode set at maximum. Then, we ex-
tracted the common genes present in the centroids and
our expression file to calculate the pearson correlation for
each centroid to each sample (classification script is pro-
vided as Additional file 4) using the R software. Further-
more, hierarchical clustering and heatmap plots were
generated with the heatmap.2 function included in the
gplots library in R software using Pearson correlation
values calculated previously for each centroid to each sam-
ple (Additional file 1: Table S12). Expression signatures
were re-named as “Urobasal A” (MS1a-b), “Genomically
unstable” (MS2a1-2),“Urobasal B” (MS2b2.1) and “SCC-
like” (MS2b2.2). The “Infiltrated” phenotype was not con-
sidered as it is mainly based on a stromal signature.
The same approach was applied using the centroids
provided by Rebouissou et al. [25] to classify cell lines as
“basal” or “non-basal” with the respective confidence
prediction (Additional file 1: Table S13).
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